{"id":28678,"date":"2024-07-11T17:49:42","date_gmt":"2024-07-11T12:19:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28678"},"modified":"2024-07-11T17:49:45","modified_gmt":"2024-07-11T12:19:45","slug":"medtech-news-for-cordis-forma-medical-virpax","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax","title":{"rendered":"Cordis FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device;\u00a0 Forma Medical\u2019s Optimal Plating System FDA Approval; Virpax\u2019s Swine Model Pilot Study Positive Results; SetPoint Medical Positive Topline Results from Pioneering RESET-RA Study; Signature Orthopaedics Partnered with THINK Surgical; Nusano and PharmaLogic Formed Strategic Supply Agreement"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2c5cf87858\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2c5cf87858\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#Cordis_Secured_FDA_Approval_for_MYNX_CONTROL_VENOUS_Vascular_Closure_Device_Expanding_Proven_MYNX_Technology_to_Mid-Bore_Venous_Puncture_Sites\" >Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#FDA_Cleared_Forma_Medicals_Optimal_Plating_System_Enhancing_MIS_Forefoot_Portfolio_Growth\" >FDA Cleared Forma Medical\u2019s Optimal Plating System, Enhancing MIS Forefoot Portfolio Growth&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#Virpax_Reported_Positive_Outcomes_from_Swine_Model_Pilot_Study_for_Probudur%E2%84%A2\" >Virpax Reported Positive Outcomes from Swine Model Pilot Study for Probudur\u2122<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#SetPoint_Medical_Reported_Positive_Topline_Results_from_Pioneering_RESET-RA_Study_on_Neuroimmune_Modulation_for_Rheumatoid_Arthritis\" >SetPoint Medical Reported Positive Topline Results from Pioneering RESET-RA Study on Neuroimmune Modulation for Rheumatoid Arthritis&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#Signature_Orthopaedics_Partnered_with_THINK_Surgical_for_Robotic_Total_Knee_Arthroplasty\" >Signature Orthopaedics Partnered with THINK Surgical for Robotic Total Knee Arthroplasty&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\/#Nusano_and_PharmaLogic_Formed_Strategic_Supply_Agreement_to_Boost_Radiopharmaceuticals\" >Nusano and PharmaLogic Formed Strategic Supply Agreement to Boost Radiopharmaceuticals&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-cordis-secured-fda-approval-for-mynx-control-venous-vascular-closure-device-expanding-proven-mynx-technology-to-mid-bore-venous-puncture-sites\"><span class=\"ez-toc-section\" id=\"Cordis_Secured_FDA_Approval_for_MYNX_CONTROL_VENOUS_Vascular_Closure_Device_Expanding_Proven_MYNX_Technology_to_Mid-Bore_Venous_Puncture_Sites\"><\/span><strong>Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 9, 2024, Cordis, a leading company in cardiovascular and endovascular technology, received FDA approval for its MYNX CONTROL\u2122 VENOUS Vascular Closure Device. This device is approved for use in procedures with access sites ranging from 6F to 12F.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cUsing MYNX CONTROL\u2122 VENOUS VCD following ablation procedures, investigators achieved consistent and effective closure, facilitating quick and safe patient ambulation,\u201d said Dr. John Summers, Director of Cardiac Electrophysiology at the SSM Health St. Anthony Hospital and Cardiology Chief at SSM Health St. Anthony Hospital Midwest. \u201cThe ReliaSeal results demonstrate superiority to manual compression and will allow electrophysiologists to confidently increase procedure efficiency.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>The MYNX CONTROL\u2122 VENOUS VCD adds to Cordis&#8217; range of easy-to-use vascular closure devices. It uses GRIP TECHNOLOGY\u2122 with a hydrophilic, bioinert PEG sealant that absorbs three times faster than collagen sealants and provides the fastest hemostasis of any venous closure device. In a clinical trial comparing it to manual compression during cardiac ablation procedures, MYNX CONTROL\u2122 VCD achieved 100% success. The trial showed it significantly reduced time to hemostasis (2.1 vs. 11.4 minutes), time to ambulation (2.6 vs. 5.14 hours), and time to discharge eligibility (3.1 vs. 5.5 hours), improving hospital workflow.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cMYNX CONTROL\u2122 VENOUS VCD demonstrates Cordis\u2019 commitment to innovation and will offer immediate value to physicians and patients\u201d said Chris Bingham, Vice President, Global Marketing &amp; Strategy at Cordis.\u201cCordis is building a robust portfolio of products across the coronary, peripheral and closure markets. We look forward to bringing transformative innovation to market, benefitting both patients and physicians.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-closure-devices-market\"><strong>Vascular Closure Device Market Report<\/strong><\/a>,\u201d the global vascular closure device market was valued at <strong>USD 1.11 billion<\/strong> in 2023, growing at a <strong>CAGR of 6.18%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 1.59 billion<\/strong> by 2030. Factors such as the growing prevalence of cardiovascular disorders such as heart strokes, the rising prevalence of risk factors associated with cardiovascular diseases such as obesity and hypertension, the increasing geriatric population, and the surge in the popularity of minimally invasive procedures, are expected to drive the vascular closure devices market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-cleared-forma-medical-s-optimal-plating-system-enhancing-mis-forefoot-portfolio-growth-nbsp\"><span class=\"ez-toc-section\" id=\"FDA_Cleared_Forma_Medicals_Optimal_Plating_System_Enhancing_MIS_Forefoot_Portfolio_Growth\"><\/span><strong>FDA Cleared Forma Medical\u2019s Optimal Plating System, Enhancing MIS Forefoot Portfolio Growth&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 9, 2024, Forma Medical Inc., a top innovator in medical devices, announced FDA 510(k) clearance for its new OptimalMTP\u00ae Plating System. This approval is a major advancement in minimally invasive surgery, bringing more precision and efficiency to foot and ankle surgeries, a rapidly growing area in the medical device field.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;The FDA clearance of our Optimal Plating System marks a pivotal moment for Forma Medical and the orthopedic community at large,&#8221; remarked Chris Cole, VP of Sales at Forma Medical. &#8220;We are excited to introduce a transformative platform that not only enhances surgical outcomes but also elevates the standard of care for patients undergoing orthopedic foot and ankle procedures.&#8221;&nbsp;<\/p>\n<\/blockquote>\n\n\n\n<p>Forma Medical specializes in bunion-related procedures, and with the approval of the OptimalMTP\u00ae Plating System, it is well-equipped to meet the changing needs of both surgeons and patients. The company strives to set new standards in minimally invasive surgery by offering customized solutions that improve the efficiency and effectiveness of foot and ankle surgeries.<\/p>\n\n\n\n<p>The Optimal Plating System launch is headlined by OptimalMTP\u00ae, the first system for less invasive MTP Fusion of the first ray. This flagship product, along with OptimalHT\u00ae and OptimalAkin, demonstrates Forma Medical&#8217;s commitment to innovation and patient care. These solutions help surgeons address complex orthopedic problems more efficiently and with less invasiveness compared to standard treatments.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/minimally-invasive-surgical-mis-devices-market\"><strong>Minimally Invasive Surgical (MIS) Devices Market Report<\/strong><\/a>, the global MIS devices market was valued at <strong>USD 28,873.25 million <\/strong>in 2023, growing at a <strong>CAGR of 7.38%<\/strong> during the forecast period from 2024 to 2030, in order to reach <strong>USD 42,499 million<\/strong> by 2030. The MIS devices market is witnessing a positive market growth owing to the factors such as rising prevalence of various cancers such as lung cancer which accounted for the highest number of cancer-related deaths and highest cancer incidence in 2023, and other indications such as cardiovascular diseases, and neurodegenerative diseases among others. Furthermore, the presence of factors such as growth in aging population wherein age plays a key role in the development of various indications is another factor driving the growth of the MIS devices market. Moreover, the technological advancements in product development such as the development of surgical robots is further driving the MIS devices market as new products are gaining regulatory approvals and are entering the market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-virpax-reported-positive-outcomes-from-swine-model-pilot-study-for-probudur\"><span class=\"ez-toc-section\" id=\"Virpax_Reported_Positive_Outcomes_from_Swine_Model_Pilot_Study_for_Probudur%E2%84%A2\"><\/span><strong>Virpax Reported Positive Outcomes from Swine Model Pilot Study for Probudur\u2122<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 10, 2024, Virpax\u00ae Pharmaceuticals, Inc., which focuses on non-addictive products for pain, post-traumatic stress disorder, central nervous system disorders, and antiviral barriers, announced the results of a Swine Model pilot study for Probudur. Probudur is a long-lasting liposomal bupivacaine injection for wound sites that provides both immediate and extended pain relief.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cOur study results to date for Probudur, as expected, have consistently been positive and support our belief that Probudur has the potential to provide both immediate relief as well as sustained relief at the wound site,\u201d stated Gerald Bruce, CEO of Virpax Pharmaceuticals. \u201cWith our agreement to negotiate additional funding from our new institutional investor, and remaining necessary studies underway, we continue to target the end of the year for filing our Investigational New Drug Application (IND) for Probudur.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>The study of Probudur in the Swine Model focused on its effects and safety. The drug was injected under the skin of four young pigs at a dose of 30 mg\/kg. It was well-tolerated by all pigs, showing a slow, long-lasting release. Histopathology at the injection site also confirmed the drug&#8217;s safety.<\/p>\n\n\n\n<p>Probudur is being created to reduce or eliminate the use of opioids after surgery in approved cases. It acts as a local anesthetic by blocking pain signals from reaching the brain through sodium channels. In tests before clinical trials, Probudur has effectively controlled pain for at least 96 hours. Studies using a rat model of incisional pain showed pain relief for up to five days, and laboratory studies indicated a gradual release of bupivacaine that lasted up to six days.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/pain-management-devices-market\"><strong>Pain Management Devices Market Report<\/strong><\/a>\u201d, the global pain management devices market was valued at<strong> USD 4.86 billion<\/strong> in 2023, growing at a <strong>CAGR of 7.90% <\/strong>during the forecast period from 2024 to 2030, to reach <strong>USD 7.67 billion<\/strong> by 2030. The demand for pain management devices is primarily motivated by the rise in the prevalence of chronic pain, the high prevalence of musculoskeletal disorders, the surge in the geriatric population, the surge in awareness among people toward pain management devices, improved R&amp;D investment to develop innovative products, and increasing cost of healthcare expenditure.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-setpoint-medical-reported-positive-topline-results-from-pioneering-reset-ra-study-on-neuroimmune-modulation-for-rheumatoid-arthritis-nbsp\"><span class=\"ez-toc-section\" id=\"SetPoint_Medical_Reported_Positive_Topline_Results_from_Pioneering_RESET-RA_Study_on_Neuroimmune_Modulation_for_Rheumatoid_Arthritis\"><\/span><strong>SetPoint Medical Reported Positive Topline Results from Pioneering RESET-RA Study on Neuroimmune Modulation for Rheumatoid Arthritis&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 10, 2024, SetPoint Medical, a company focused on treating chronic autoimmune diseases, announced positive results from the RESET-RA study. This study tested the SetPoint System as a new neuroimmune treatment for adults with moderate-to-severe rheumatoid arthritis who don&#8217;t respond well to or can&#8217;t tolerate traditional disease-modifying anti-rheumatic drugs.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cDespite multiple treatment options, including biologic therapies and oral Janus kinase (JAK) inhibitors, there continue to be challenges and unmet medical needs in managing rheumatoid arthritis,\u201d said David Chernoff, M.D., Chief Medical Officer of SetPoint Medical. \u201cA significant proportion of patients either do not adequately respond to or are intolerant to currently approved treatment options. Approved therapies can also have serious immunosuppressive risks leading to safety concerns, poor patient satisfaction, and low treatment adherence.\u201d&nbsp;<\/p>\n<\/blockquote>\n\n\n\n<p>The study achieved its main goal, with significantly more participants in the treatment group reaching an ACR20 response compared to the control group at 12 weeks (p=0.0209). An ACR20 response is a measure of RA treatment effectiveness by the American College of Rheumatology. No safety issues were observed during the first 12 weeks or in long-term follow-up. Adverse event rates were low for both the implant procedure and stimulation therapy. Overall, the treatment was effective and well-tolerated.<\/p>\n\n\n\n<p>RESET-RA is a pivotal trial conducted in two stages, involving multiple centers, and is randomized, sham-controlled, and double-blind. It enrolled 242 patients at 41 sites across the U.S. After reaching the primary endpoint at 12 weeks, the study is now continuing to assess the long-term safety and effectiveness of the device in an open-label extension.<\/p>\n\n\n\n<p>The SetPoint System features an implantable, rechargeable neurostimulation device that stimulates the vagus nerve once a day. This activation of anti-inflammatory and immune-restorative pathways offers a way to treat autoimmune conditions like RA without the risks of immunosuppression that come with drug therapies. After a simple outpatient procedure to place the device, it is programmed to automatically deliver therapy on a set schedule, ensuring better compliance and persistence with treatment.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are thrilled with the results from the RESET-RA study as they highlight the potential of the SetPoint System for providing rheumatologists and their patients with a safe and effective treatment alternative to current rheumatoid arthritis therapies,\u201d said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. \u201cAs next steps, we look forward to submitting the data for presentation at upcoming rheumatology and neurosurgical medical meetings, and completing our premarket approval submission to the FDA.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neurostimulation-devices-market\"><strong>Neurostimulation Devices Market Report<\/strong><\/a>\u201d, the global neurostimulation devices market was valued at<strong> USD 5.82 billion<\/strong> in 2023, growing at a <strong>CAGR of 11.77%<\/strong> during the forecast period from 2024 to 2030, to reach <strong>USD 11.34 billion<\/strong> by 2030. The demand for neurostimulation devices is primarily motivated by the increasing incidence of chronic neurological diseases, such as migraine and epilepsy, escalating product demand as add-on therapy, the prevalence of lifestyle diseases such as depression and chronic pain, the adoption of technologically advanced products, and rising geriatric population among others during the forecast period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-signature-orthopaedics-partnered-with-think-surgical-for-robotic-total-knee-arthroplasty-nbsp\"><span class=\"ez-toc-section\" id=\"Signature_Orthopaedics_Partnered_with_THINK_Surgical_for_Robotic_Total_Knee_Arthroplasty\"><\/span><strong>Signature Orthopaedics Partnered with THINK Surgical for Robotic Total Knee Arthroplasty&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 9, 2024, THINK Surgical, Inc., a leading innovator in orthopedic surgical robots, announced a collaboration with Signature Orthopaedics (SignatureOrtho\u2122), an Australian company specializing in orthopedic device design. Through this partnership, THINK Surgical will integrate SignatureOrtho&#8217;s advanced knee design into its proprietary ID-HUB\u2122 data bank of implant modules, to be used with the TMINI\u00ae Miniature Robotic System.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are thrilled to collaborate with THINK Surgical to offer a robotic solution to our customers\u201d said Declan Brazil, Chief Executive Officer of Signature Orthopaedics. \u201cThis partnership highlights our dedication to innovation and our responsiveness to customer feedback. Together, we aim to enhance surgical precision and improve patient outcomes through this innovative effort.\u201d<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cTHINK Surgical is committed to maximizing our implant agnostic platform and we are excited about this new collaboration with SignatureOrtho that will enable even more choice for customers using TMINI,\u201d said Stuart Simpson, President and Chief Executive Officer of THINK Surgical.<\/p>\n<\/blockquote>\n\n\n\n<p>THINK Surgical is committed to providing open-platform orthopedic surgical robots that support implants from multiple manufacturers. The addition of the SignatureOrtho knee system to THINK Surgical\u2019s ID-HUB database will allow SignatureOrtho customers access to robotic-assisted technology for total knee replacement. The development of the implant module for use with the TMINI System is in progress.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/total-knee-arthroplasty-market\"><strong>Total Knee Arthroplasty Market Report<\/strong><\/a>\u201d, the global knee replacement market size is estimated at <strong>USD 11.74 billion<\/strong> in 2023 and is expected to reach <strong>USD 14.80 billion <\/strong>by 2024, growing at a<strong> CAGR of 4.73%<\/strong> during the forecast period from 2024 to 2030. The demand for total knee arthroplasty is primarily motivated by the increasing incidence of road accidents leading to amputations, increasing prevalence of osteoarthritis &amp; rise in the number of knee injury cases, and technological advancement across the globe during the forecasted period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nusano-and-pharmalogic-formed-strategic-supply-agreement-to-boost-radiopharmaceuticals-nbsp\"><span class=\"ez-toc-section\" id=\"Nusano_and_PharmaLogic_Formed_Strategic_Supply_Agreement_to_Boost_Radiopharmaceuticals\"><\/span><strong>Nusano and PharmaLogic Formed Strategic Supply Agreement to Boost Radiopharmaceuticals&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On July 10, 2024, Nusano Inc., a company revolutionizing medical radioisotope production, and PharmaLogic Holdings Corp., a top radiopharmaceutical CDMO, announced a supply agreement. This deal ensured a more efficient and reliable supply of essential radioisotopes. Nusano will provide on-demand radioisotopes for pharmaceutical products made in PharmaLogic&#8217;s facilities.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cPartnering with innovative companies like Nusano enhances our capabilities to meet the unique needs of our customers,\u201d said James Beatty, vice president of development and commercialization for PharmaLogic. \u201cPharmaLogic is excited to collaborate with Nusano in our shared commitment to quality and advancement in radiopharmaceutical diagnostics and therapies.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>As part of the agreement, Nusano will work with PharmaLogic to establish a radionuclide production schedule before the initial orders are placed, ensuring it meets the needs of PharmaLogic and its customers. The priority radioisotopes include lutetium-177, actinium-225, copper-67, and astatine-211. The companies will review and adjust the supply agreement each year to keep up with the changing demands of the radiopharmaceutical industry.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cNusano is bringing unparalleled production capacity and flexibility to the market,\u201d said Chris Lowe, CEO of Nusano. \u201cOur proprietary production platform will be capable of making a full menu of radioisotopes of interest to healthcare and up to 12 different isotopes simultaneously. We look forward to working with PharmaLogic and its collaborators to alleviate supply chain pressures so they can focus on advancing new therapies for cancer patients.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/nuclear-medicine-radiopharmaceuticals-market\"><strong>Nuclear Medicine\/Radiopharmaceuticals Market Report<\/strong><\/a>\u201d, the global nuclear medicine\/radiopharmaceuticals market was valued at <strong>USD 7,203.62 million<\/strong> in 2023 and is estimated to grow at a <strong>CAGR of 9.67% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 12,495 million<\/strong> by 2030. The nuclear medicine\/radiopharmaceuticals market is observing substantial market growth due to the growing prevalence of cancer, cardiovascular, and other chronic diseases owing to the inactive routine. Further, the increasing number of the geriatric population prone to chronic diseases, increasing demand for image-guided procedures and diagnostics across the world, and presence of robust products in the pipeline will propel the demand for nuclear medicine during the forecast period. Additionally, favorable government initiatives to improve access to nuclear medicine and research collaborations and partnerships will also aid in driving the market of nuclear medicine. Likewise, the increasing research &amp; developmental activities along with the surging nuclear medicine approvals and radiopharmaceutical diagnosis device launches, the presence of key players in the market, and other factors will create a requisite for the nuclear medicine\/radiopharmaceuticals in the market. Therefore, the market for nuclear medicine\/radiopharmaceuticals is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiovascular and endovascular technology, received FDA approval for its MYNX CONTROL\u2122 VENOUS Vascular Closure Device. This device is approved for use in procedures with access sites [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28680,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2753,17021,16975,19587,19143,19351,20066,21247,19147,19464,19588],"industry":[17226],"therapeutic_areas":[17242,17245],"class_list":["post-28678","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-minimally-invasive-surgical-mis-devices","tag-neurostimulation-devices","tag-neurostimulation-devices-market","tag-nuclear-medicine","tag-pain-management-devices","tag-total-knee-arthroplasty","tag-vascular-closure-devices","tag-minimally-invasive-surgical-mis-devices-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Medtech News | Cordis, Forma Medical, Virpax<\/title>\n<meta name=\"description\" content=\"Cordis\u2019 MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical\u2019s Optimal Plating System; Virpax\u2019s Swine Model Pilot Study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtech News | Cordis, Forma Medical, Virpax\" \/>\n<meta property=\"og:description\" content=\"Cordis\u2019 MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical\u2019s Optimal Plating System; Virpax\u2019s Swine Model Pilot Study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-11T12:19:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-11T12:19:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medtech News | Cordis, Forma Medical, Virpax","description":"Cordis\u2019 MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical\u2019s Optimal Plating System; Virpax\u2019s Swine Model Pilot Study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax","og_locale":"en_US","og_type":"article","og_title":"Medtech News | Cordis, Forma Medical, Virpax","og_description":"Cordis\u2019 MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical\u2019s Optimal Plating System; Virpax\u2019s Swine Model Pilot Study","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-07-11T12:19:42+00:00","article_modified_time":"2024-07-11T12:19:45+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax","name":"Medtech News | Cordis, Forma Medical, Virpax","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax.png","datePublished":"2024-07-11T12:19:42+00:00","dateModified":"2024-07-11T12:19:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Cordis\u2019 MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical\u2019s Optimal Plating System; Virpax\u2019s Swine Model Pilot Study","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-cordis-forma-medical-virpax#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax.png","width":772,"height":482,"caption":"medtech-news-for-cordis-forma-medical-virpax"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/11174803\/medtech-news-for-cordis-forma-medical-virpax-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Minimally Invasive Surgical (MIS) Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurostimulation Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurostimulation Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nuclear Medicine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pain Management Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Total Knee Arthroplasty<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vascular Closure Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">\u2018Minimally Invasive Surgical (MIS) Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Minimally Invasive Surgical (MIS) Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurostimulation Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurostimulation Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Nuclear Medicine<\/span>","<span class=\"advgb-post-tax-term\">Pain Management Devices<\/span>","<span class=\"advgb-post-tax-term\">Total Knee Arthroplasty<\/span>","<span class=\"advgb-post-tax-term\">Vascular Closure Devices<\/span>","<span class=\"advgb-post-tax-term\">\u2018Minimally Invasive Surgical (MIS) Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jul 11, 2024","modified":"Updated on Jul 11, 2024"},"absolute_dates_time":{"created":"Posted on Jul 11, 2024 5:49 pm","modified":"Updated on Jul 11, 2024 5:49 pm"},"featured_img_caption":"medtech-news-for-cordis-forma-medical-virpax","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28678"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28678\/revisions"}],"predecessor-version":[{"id":28681,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28678\/revisions\/28681"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28680"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28678"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28678"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}